dc.contributor.author | Mbori-Ngacha, DA | |
dc.contributor.author | Richardson, BA | |
dc.contributor.author | Overbaugh, J | |
dc.contributor.author | Panteleeff, DD | |
dc.contributor.author | Nduati, RW | |
dc.contributor.author | Steele, M | |
dc.contributor.author | John-Stewart, G | |
dc.date.accessioned | 2013-06-10T07:53:22Z | |
dc.date.available | 2013-06-10T07:53:22Z | |
dc.date.issued | 2003-07 | |
dc.identifier.citation | J Virol. 2003 Jul;77(13):7702-5. | en |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/pubmed/12805473 | |
dc.identifier.uri | http://erepository.uonbi.ac.ke:8080/xmlui/handle/123456789/30446 | |
dc.description.abstract | The effect of zidovudine on plasma and genital human immunodeficiency virus type 1 (HIV-1) was determined in 42 antiretroviral-naive HIV-1-seropositive women in Nairobi. After 7 days of zidovudine treatment, HIV-1 RNA levels decreased by 0.5 to 1.1 log(10) in plasma and genital secretions. HIV-1 RNA half-life following zidovudine treatment was 4.7, 1.3, and 0.9 days in plasma, cervix, and vagina, respectively, and significantly shorter in genital secretions than in plasma (P < 0.001). Defining the short-term effect of zidovudine on plasma and genital HIV-1 is important for improving perinatal HIV-1 interventions | en |
dc.language.iso | en | en |
dc.publisher | University of Nairobi. | en |
dc.title | Short-term effect of zidovudine on plasma and genital human immunodeficiency virus type 1 and viral turnover in these compartments | en |
dc.type | Article | en |
local.publisher | Department of Pediatrics, University of Nairobi, Nairobi, Kenya | en |